An LSA/iso-LSA-rich ergot preparation, at doses achievable from about a gram of ergot, would reliably produce the profound and largely positive visionary experience attributed to Eleusinian initiation.

LSA is psychoactive and can hallucinate, but the human literature is sedating, nauseating and occasionally dangerous (TIK-E012), and the reconstructed preparation has never been profiled (TIK-R003). Psilocybin trials (TIK-E013) show the experience type is inducible, not that this compound induces it.

LSA is psychoactive but substantially weaker than LSD, with nausea, autonomic and anxiety effects prominent in the human literature (TIK-E012), and the lye-processed preparation itself has never been profiled in vivo. 'Reliably profound and largely positive' is the step the evidence does not reach.

The systematic review (TIK-E012) supports LSA psychoactivity and hallucination but documents nausea, autonomic distress and anxiety as prominent, with much lower potency than LSD; the reconstructed extract has never been profiled in vivo (TIK-R003). 'Reliably profound and positive' is unearned.

While LSA is demonstrably psychoactive and can occasion euphoria, systematic reviews indicate its human pharmacological profile is significantly weaker than LSD and frequently marred by prominent sedation, nausea, and autonomic distress. The strongest opposing consideration is that the full reconstructed alkaline ergot extract has never undergone receptor profiling or human toxicology, leaving it entirely unproven whether this specific matrix could reliably generate the profoundly positive, transcendent experiences attributed to Eleusis.

It is well supported that LSA reaches the brain, produces hallucinations in some cases, and is substantially weaker than LSD, with significant nausea and autonomic side effects documented; this comes from the 2025 systematic review and related pharmacology. However, there is no direct data on the full lye-processed ergot mixture’s human effects, and no controlled studies showing that a gram-equivalent dose reliably causes the kind of overwhelmingly positive, transformative group experience claimed for Eleusis. The strongest objection is precisely this lack of empirical data on the specific preparation and dosing regime hypothesized, which leaves the experiential claim speculative.

LSA reaches the brain, is psychoactive, and can produce hallucinations and euphoria, and modern psilocybin trials show that pharmacologically occasioned mystical-type experience is real — but psilocybin is not LSA, and those trials are analogy, not history. The 2025 systematic review documents prominent nausea, autonomic effects, anxiety, and occasional severe outcomes in the human LSA literature, which is dominated by morning-glory-seed exposures rather than lye-processed ergot. The strongest opposing consideration is the claim as stated: nothing establishes that an iso-LSA-heavy crude extract at about one gram of ergot per initiate would reliably deliver the profound, largely positive experience attributed to Eleusis rather than an unpleasant sedated one, and the full reconstructed mixture has never been profiled.

The claim has separable components with divergent support: LSA reaches the brain, is psychoactive, and can produce hallucinations and euphoria (TIK-E012), and pharmacologically occasioned mystical-type experience is real in modern trials (TIK-E013). But the claim as stated asserts reliability, profundity, and positivity at about a gram of ergot — and the human LSA literature is dominated by morning-glory exposures with prominent nausea, autonomic effects, anxiety, and occasional severe outcomes, while the full reconstructed extract has never been profiled (TIK-R003). The strongest opposing consideration is that morning-glory data may not model an iso-LSA-rich lye extract, and Eleusinian set and setting could carry much of the phenomenology — which keeps this mixed rather than contradicted. As stated, "reliably produce the profound, largely positive experience" is the component without support.

The claim conjoins four things and the evidence stops at the third: LSA reaches the brain, is psychoactive, and can produce hallucinations and euphoria (TIK-E012), but nothing supports the reliability and positive valence at achievable dose that the claim asserts. The same systematic review documents prominent nausea, autonomic effects, anxiety and occasional severe outcomes, which points against rather than towards the "best night of your life" phenomenology, and the yield figures imply roughly a milligram of combined lysergamides per gram of ergot — a marginal extrapolation for a mass-administered rite. The strongest opposing consideration is matrix mismatch in the other direction: the human record is dominated by morning-glory-seed exposures whose vegetative burden may come from seed constituents rather than LSA itself, and the reconstructed extract has never been profiled (TIK-R003), so the negative signal is suggestive rather than decisive. TIK-E013 shows only that some pharmacology can occasion mystical experience, not that this one would.

LSA is psychoactive and can hallucinate; the human record is also sedating, nauseating, and occasionally dangerous, and the full reconstructed preparation has never been profiled (TIK-R003). The experiential premise of the hypothesis is genuinely open.

LSA is psychoactive, but the human record (TIK-E012) is nausea, sedation, autonomic effects, and anxiety as often as vision, and the reconstructed extract has never been profiled. Grok and GPT-5.1 both stress that 'related to LSD' is doing unearned work; agreed.

The systematic review (TIK-E012) confirms LSA is psychoactive but documents nausea, autonomic and vegetative effects, and anxiety as prominent, at substantially lower potency than LSD, with human data drawn from morning-glory seeds rather than the reconstructed extract. 'Reliably profound and positive at ~1 g of ergot' remains an extrapolation, not a finding.

The components with meaningful support: LSA reaches the brain, is psychoactive, and can produce hallucinations and euphoria (TIK-E012); pharmacologically induced mystical-type experience is real in modern trials (TIK-E013). The component without it: that this preparation at this dose reliably yields the profound, positive, mass-administered experience the Mysteries were famous for — the systematic review documents prominent nausea, autonomic effects, anxiety, and occasional severe outcomes, and the full reconstructed mixture has never been profiled (TIK-R003).

TIK-E012 shows LSA is psychoactive but substantially weaker than LSD with prominent nausea, autonomic effects and anxiety in the human record; TIK-E013 shows the pharmacological route to mystical experience is real for a different molecule. The reconstructed extract has never been profiled; the proposed pennyroyal synergy is untested.

TIK-E012 qualifies: LSA is psychoactive but weaker than LSD, with nausea, autonomic effects and anxiety prominent in a human record dominated by morning-glory exposures; TIK-E013 shows pharmacological mystical experience is real for a different molecule. The reconstructed extract has never been profiled.

While LSA is an active lysergamide, systematic clinical and toxicological reviews demonstrate that it produces heavy sedation, autonomic distress, nausea, and dysphoria, differing substantially from the profound, reliably transcendent mystical states celebrated at Eleusis. The strongest opposing consideration is that ritual set, setting, and potential botanical synergy (such as compounds in pennyroyal) could theoretically alter the subjective experience, though this remains an unproven assertion.

LSA is demonstrably psychoactive and can occasion hallucinations and euphoria, and modern psychedelic science shows pharmacologically induced mystical-type experience is real — but the systematic review documents prominent nausea, autonomic effects, anxiety, and occasional severe adverse outcomes at substantially lower potency than LSD, and the human data come from a different matrix than the reconstructed drink. The strongest opposing consideration is that "would reliably produce the profound and largely positive visionary experience" asserts precisely what no record establishes; the pennyroyal-synergy proposal added by the 2026 authors is itself untested (TIK-R013).

TIK-E012 describes LSA as psychoactive and capable of hallucinations and euphoria, but also as substantially weaker than LSD and associated with prominent nausea, autonomic effects, anxiety, and occasional severe outcomes. That record conflicts with the claim's strong prediction of a reliable, profound, and largely positive response, while TIK-E013 concerns psilocybin rather than LSA. The strongest opposing consideration is that the complete lye-processed ergot preparation has never been pharmacologically tested and could perform differently from the morning-glory-dominated exposure literature.

LSA is documented as psychoactive and capable of producing hallucinations and euphoria, and the 2026 yields show that an active dose is achievable from about a gram of ergot; modern psychedelic trials confirm that pharmacology can occasion mystical-type experience. However, the systematic review shows LSA is substantially weaker than LSD and carries prominent adverse effects (nausea, anxiety, autonomic instability, occasional severe events), so “reliably” and “largely positive” profound visionary experience is not established for the reconstructed preparation. The strongest opposing consideration is the complete absence of any human or even full-matrix animal profile of the actual lye-processed ergot drink.

Nothing in the ledger profiles the reconstructed preparation (R003), and what does exist qualifies the claim. E012 finds LSA psychoactive and able to produce hallucinations and euphoria, but much less potent than LSD and accompanied by prominent nausea, autonomic effects, anxiety and occasional severe adverse events. C033 puts a gram of ergot at about the threshold dose, and C029 leaves ergometrine in the mix. E013 shows drug-induced mystical experience is real, but for psilocybin in a modern laboratory, so support stops at "psychoactive"; "reliably", "profound" and "largely positive" at gram-scale doses are unsupported and in tension with E012. Strongest opposing consideration: E012's human data come mostly from morning-glory seeds, and the full mixture, ritual setting and proposed pennyroyal potentiation (R013) are untested and could raise intensity or improve the experience; my expectation that sub-milligram LSA often sedates rather than inspires is general background, a prior I disclose.

In humans LSA is psychoactive, with hallucinations and euphoria, but weaker than LSD and marked by nausea, sedation and anxiety (TIK-E012). Psilocybin trials show drugs can occasion mystical experience (TIK-E013), but with a different molecule. The reconstructed drink has never been profiled, so 'reliably profound and positive' is neither shown nor refuted.